Company intelligence / Profile preview
Anlong Bio
Beijing Shunyi, Beijing, Chinaanlongbio.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
AL-001 Ophthalmic Injection for wet AMD has entered clinical trials and was approved by the institutional project establishment and ethics committee of Peking Union Medical College Hospital in May 2023[8]. The company has a second product (KW-040) for Hepatitis B in preclinical stage[4].
- Therapeutic areas
- OphthalmologyInfectious Diseases
- Modalities
- AAV-based gene therapysiRNAnucleic acid drugs
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Tsinghua UniversityCapital Medical UniversityChinese Organization for Rare Disorders
Beyond the preview
Go deeper on Anlong Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anlong Bio.